Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 14-year-old female with tufted hair folliculitis, where isotretinoin reduced inflammation and exudation but persistent hair tufting remained, highlighting the challenges in treating this rare condition.

This article reviews current knowledge about diffuse telogen effluvium, focusing on its classification, clinical features, causes, and diagnostic and treatment approaches.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This study observed that combining PRP and Tressfix Serum significantly improved hair regrowth and reduced microRNA expression linked to Chronic Telogen Effluvium compared to using either treatment alone.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This study found that patients with Telogen Effluvium had significantly higher levels of scalp pain and itching, and serum ferritin levels could effectively differentiate them from healthy controls.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.

This study found that female patients with telogen effluvium had significantly lower levels of serum ferritin, folate, and vitamin B12 compared to the control group.

Teledermatology reduces unnecessary in-person visits and improves care.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This study found that tenuazonic acid from Alternaria alternata can cause significant damage to vital organs in mice at low doses and highlights the need for regulatory measures to manage its risk in agricultural products.

This case series reported that telogen effluvium may reveal underlying traction alopecia, emphasizing the importance of recognizing this to ensure accurate diagnosis and treatment.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

In this case report, a 39-year-old woman's symptoms from dermatomyositis–systemic lupus erythematosus overlap syndrome improved only after she was treated with tofacitinib.

This study found that female patients with telogen effluvium had significantly lower serum ferritin levels compared to healthy individuals, suggesting an association between low ferritin and this condition.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

Using finasteride with TIP extends time off period for prostate cancer patients.

In this study, researchers observed that deficiency in biochemical markers, notably ferritin and serum iron, is frequently found in female patients diagnosed with telogen effluvium, suggesting these tests are crucial in understanding and treating the condition.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

Tofacitinib may effectively treat folliculitis decalvans.